• PN: B112516

COMPONENTS

45x Ab-conjugated beads (S4P9- Human PARC Ab-bead). PN: B112516A. One vial containing 100 µL of anti-Human PARC conjugated to AimPlex Bead S4P9.

25x Biotin-detection Ab (Human PARC Biotin-dAb). PN: B112516B. One vial containing 100 µL of biotinylated anti-Human PARC.

Lyophilized Standard Mix-Human Group 7, Panel B, 7-Plex. PN: HG72006. One vial containing lyophilized recombinant NAP-2, PARC, sPD-1, PF4, SDF-1, TARC, and TECK.  Note: If multiple analyte kits on the above target list are ordered as a panel, only one vial of standard mix is supplied for those analyte kits.

STORAGE:  2-8 C in the dark.

IMPORTANT: Sodium azide forms explosive compounds with heavy metals. These products contain <0.05% (w/w) azide which with repeated contact with lead and copper commonly found in plumbing drains may result in the buildup of shock sensitive compounds. Dispose in accordance with regulations from your institute.

APPLICATION: Optimal antibody pair and antigen standard for assaying human CCL18/SCYA18/PARC. Can be multiplexed with other analytes in Human Group 7.  To be used in conjunction with the AimPlex NR Basic Kit (PN: P100001) and a diluent kit. Refer to the AimPlex Multiplex Immunoassay User Manual and kit inserts for the assay procedure.

For Research Use Only.  Not for use in diagnostic procedures.

Assay Specifications:

Sample types: Cell culture supernatant, serum, plasma, bodily fluid and tissue/cell lysate

Sensitivity (LOD): < 5 pg/mL

Quantitation range:

LLOQ: < 10 pg/mL

ULOQ: > 2,000 pg/mL

Standard dose recovery: 70-130%

Intra-assay CV: < 10%

Inter-assay CV: < 20%

Cross-reactivity of analytes in Human Group 7: Negligible

Sample volume: 15 µL/test

Description:

Chemokine (C-C motif) ligand 18 (CCL18) is a small cytokine belonging to the CC chemokine family. It was previously known as Pulmonary and activation-regulated chemokine (PARC), small inducible cytokine A18 (SYCA18), dendritic cell (DC)-chemokine 1 (DC-CK1) and macrophage inflammatory protein-4 (MIP-4). The effector function that CCL18 exerts on the immune system is mainly on the adaptive immune system, while being produced and secreted mainly by innate immune system. CCL18 also has strong immunosuppressive effects. CCL18 induces immature dendritic cells to differentiate into an immunosuppressive dendritic cell that is capable producing CCL18 which attract T-cells, suppressing effector T-cell function, and generating T-regulatory cells by secreting large amounts of IL-10. Exposure to CCL18 by macrophages causes them to mature in the #M2 spectrum, which promotes immunosuppression and healing. Diseases associated with CCL18 include allergic asthma and pulmonary fibrosis.

References:

1.      Hieshima K, Imai T, Baba M, Shoudai K, Ishizuka K, Nakagawa T, Tsuruta J, Takeya M, Sakaki Y, Takatsuki K, Miura R, Opdenakker G, Van Damme J, Yoshie O, Nomiyama H (August 1997). "A novel human CC chemokine PARC that is most homologous to macrophage-inflammatory protein-1 alpha/LD78 alpha and chemotactic for T lymphocytes, but not for monocytes". J. Immunol. 159 (3): 1140–9. PMID 9233607.

2.      Politz O, Kodelja V, Guillot P, Orfanos CE, Goerdt S (February 2000). "Pseudoexons and regulatory elements in the genomic sequence of the beta-chemokine, alternative macrophage activation-associated CC-chemokine (AMAC)-1". Cytokine 12 (2): 120–6. doi:10.1006/cyto.1999.0538. PMID 10671296.

3.      Tasaki Y, Fukuda S, Iio M, Miura R, Imai T, Sugano S, Yoshie O, Hughes AL, Nomiyama H (February 1999). "Chemokine PARC gene (SCYA18) generated by fusion of two MIP-1alpha/LD78alpha-like genes". Genomics 55 (3): 353–7. doi:10.1006/geno.1998.5670. PMID 10049593.

4.      Vulcano M, Struyf S, Scapini P, Cassatella M, Bernasconi S, Bonecchi R, Calleri A, Penna G, Adorini L, Luini W, Mantovani A, Van Damme J, Sozzani S (April 2003). "Unique regulation of CCL18 production by maturing dendritic cells". J. Immunol. 170 (7): 3843–9. doi:10.4049/jimmunol.170.7.3843. PMID 12646652